ERBB2 and colorectal carcinoma: An ongoing phase I study (NCT04319757) is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing tumors, including CRC.